Cardiometabolic Disease, Diabetes & Obesity

Highlights the intersection between metabolic dysregulation, kidney function, and cardiovascular risk.

Sub-topics:

• GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists in reducing major adverse cardiovascular events (MACE)

• Cardiorenal Syndrome: Integrated management across cardiology, nephrology, and endocrinology

• Non-alcoholic fatty liver disease (NAFLD/MASH) and its direct link to systemic vascular risk